NovImmune SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NovImmune SA - overview
Established
1998
Location
Geneva, -, Switzerland
Primary Industry
Pharmaceuticals
About
NovImmune SA is a biotechnology company focused on developing innovative monoclonal antibody therapies for autoimmune diseases and immune-mediated conditions. Founded in 1998 and headquartered in Geneva, Switzerland, NovImmune SA specializes in the research and development of monoclonal antibodies. The company has completed a total of 9 deals, with the most recent investment round in January 2016, raising CHF 30 million from existing investors. The current CEO is Nicolas Fischer.
NovImmune SA specializes in innovative biotechnology solutions, particularly in monoclonal antibody development aimed at treating autoimmune diseases and immune-mediated conditions. Their core offerings include advanced therapeutic products that address complex immune system challenges, providing targeted treatments to improve patient outcomes. The revenue model for NovImmune SA is primarily based on partnership agreements and direct sales of its therapeutic products, structured around annual or multi-year contracts. This allows for a steady income stream as clients utilize their comprehensive suite of therapeutic solutions.
Their flagship products are designed to meet the needs of healthcare providers globally, ensuring a consistent revenue generation framework. NovImmune SA plans to utilize the CHF 30 million raised in January 2016 to further develop its pipeline of monoclonal antibodies. The company is focusing on launching new therapeutic products aimed at expanding its market reach in Europe and North America by 2025. Additionally, NovImmune aims to strengthen its presence in Asia through strategic partnerships with local healthcare providers.
Current Investors
BZ Bank, Akina, Novartis Venture Fund
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Biomaterials
Website
www.novimmune.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
NovImmune SA - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.